Evaluation of Light Chain Removal Rates in Blood Purification Therapy for Light Chain Cast Nephropathy

Area of Science:

• Nephrology
• Hematology
• Biochemistry

Background:

• Acute kidney injury (AKI) is a significant prognostic factor in multiple myeloma.
• Light chain cast nephropathy, caused by free light chains (FLCs) interacting with Tamm-Horsfall protein, is the primary cause of AKI in these patients.

Observation:

• Chemotherapy aims to reduce FLC production, while blood purification therapies target existing FLCs.
• The removal efficiency of FLCs by different blood purification techniques was investigated.

Findings:

• Hemodialysis demonstrated a 16% FLC removal rate.
• Plasma exchange achieved a high 75% FLC removal rate.
• Online hemodiafiltration showed variable FLC removal, ranging from 20% to 31%.

Implications:

• Plasma exchange is highly effective for FLC removal, but online hemodiafiltration presents a viable alternative without the need for albumin or risk of infection.
• Renal recovery in multiple myeloma patients with AKI may be limited by factors such as cast burden, interstitial fibrosis, tubular atrophy, and delayed treatment, even with hematologic remission.